Profits recover at Alibaba Health but prognosis unclear
The digital pharmacy and healthcare provider returned to profit in the last fiscal year but is still struggling to limit its reliance on drug sales Key Takeaways: Alibaba Health delivered…
Recent Articles
RELATED ARTICLES
-
Bumper dividend could trigger buyout for Ping An Health
1833.HK -
Earnings blow for CSPC Pharma as the state drives a hard bargain
1093.HK
-
Everest gets boost from core product Nefecon’s inclusion in China’s national health plan
1952.HK
-
Xuanzhu Biopharm set for spin-off in Hong Kong IPO
0460.HK
-
Alibaba’s breakup in tatters, could 2025 be the year of asset shedding?
9988.HK BABA.US
-
Everest Medicines eyes mRNA tumor vaccines as drug valuations rebound
1952.HK
- Cancer drug maker Genfleet joins Hong Kong IPO influx
